Impact of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity

by Yu Yu Vlasova, A S Ametov
Published 2010-08-01

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis

by M. V. Barabanshchikova, E. V. Morozova, Yu. Yu. Vlasova, V. V. Baykov, L. S. Zubarovskaya, B. V. Afanasyev
Published 2016-03-01

Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors

by EV Morozova, YuYu Vlasova, MV Barabanshchikova, NN Mamaev, IM Barkhatov, AL Alyanskii, EI Darskaya, MV Vladovskaya, SN Bondarenko, IS Moiseev, BV Afanasyev
Published 2019-03-01

New Сytogenetic Approaches in Patients with Primary Myelofibrosis

by TL Gindina, NN Mamaev, VV Baikov, MV Barabanshchikova, EN Nikolaeva, IA Petrova, IS Moiseev, OV Pirogova, YuYu Vlasova, MO Ivanova, EV Morozova, SN Bondarenko, BV Afanas’ev
Published 2016-01-01